Measuring progression through the cycle has demonstrated reliability as an independent predictor of PC-specific mortality and biochemical recurrence, aiding in risk-stratification and management decisions for PC patients, substantiated by findings in a cohort of 582 patients where CCP score was associated with both metastatic disease (HR 5.35) and BCR (HR 1.60) [43]. Here, BCR is linked to pachyonychia congenita.